Cytek Investor Day Presentation Deck
Cytek Al Expected to Speed Up the Clinical Adoption
Collaboration of Al machine learning on automatic diagnosis of B-ALL MRD
Increased accuracy with less laboratory time - Greater simplicity
CYTEK
TRANSCEND THE CONVENTIONAL
4.0M-
3.0M
2.0M-
1.OM-
10-
10⁰.
0
All Events
P1
2.0M
FSC-A
Q1607 P3
10°
CD38
Q1607 P
Count 343
10
CD10
Pant 19.78
40M
Q1607 P3
10
CD10
10"
T
10°
10°
10⁰-
Q1607 PI
P2
2.0M
FSC-A
10%
10"
10-
LOM
Q1607 P
10"
CD38
Q1607 P3
10
CD10
Q1607 P
10"
CD10
10⁰
10"
10⁰
10
10
38.47
10
01607 P2
CD64C
0
10⁰
CD38
10-
10"-
10¹
Q1607 P3
Q1607 P3
C010
01607 P
CD34
01.0M
10⁰
Q1607 P
10
TT
3.0M
SSC-A
ros
CD33 floor
BYGGIO A
10-
10-
10-
101-
3.0M
2.0M-
1.0M
TT
.
Q1607 P3
10⁰
CD38
Q1607 P3
10°
CD10
Count 101
ent: 5.50
01607 P3
CD34
01607 P
P3
Coup, 1835
CD19
10"
10
Manual Analysis with Spectro Flo
Pakol 0.37
10
CYTEK
TRANSCEND THE CONVENTIONAL
Ⓡ
A
10
10²
e
2 M
FSC-A
191 30
CD38
3M 4M
20
10 30 10
COLD
10 30
CD10
10
20%
100
30%
1M
2M
PSCA
30° 30°
CD38
C030
4M
101
10° 30 10
C030
8
30⁰
10
10
10
30
101.
2 M 3M 4M
SSC-A
20² 20 20
(338
10 10
COLO
Al Analysis
10 10
CD34
30%
0
10
10 10
CD19
10 20
COME
10 10 10
CD19
Seamless Workflow to the Clinician with Immediate Data Read
O 10 10 10
C034
102View entire presentation